- Oral presentation
- Open Access
Maraviroc (MVC) increases CD4+ and CD8+ cells: long-term data from the MVC clinical development program
© Heera et al; licensee BioMed Central Ltd. 2010
- Published: 8 November 2010
- Great Increase
- Load Change
- Background Therapy
- Clinical Development Program
Across the MVC development program, patients who received MVC-containing regimens experienced greater increases in CD4+ cell counts than those observed in comparator arms in primary analyses. Here we present longer term immunological data from this program.
Long-term (96 week) data from subjects with CCR5-tropic HIV infection in the following ongoing MVC studies were included in the analysis: (1) MOTIVATE study (MVC QD and BID vs placebo (PBO), each combined with optimized background therapy in treatment-experienced [TE] subjects); and (2) MERIT study (MVC BID vs EFV, each combined with ZDV/3TC in treatment-naïve [TN] subjects). Additionally, interim week 24 data from the ongoing 96-week 1078 study (MVC QD vs TDF/FTC, each combined with ATV/r in TN subjects) were summarized. Descriptive statistics are presented for data at baseline and at week 96 (MERIT/MOTIVATE) or week 24 (1078) pertaining to change in CD4+ and CD8+ cells.
MOTIVATE – 96 Weeks
MERIT – 96 Weeks
1078 – 24 Weeks
BL HIV RNA (median log10 cp/mL)
Baseline CD4 count (median cells/µL)
Baseline CD8 count (median cells/µL)
CD4 change from BL (median cells/µL)
CD8 change from BL (medican cells/µL)
Greater increases in CD4+ and CD8+ counts were consistently achieved with MVC-containing regimens, compared to regimens without MVC, and persisted through at least 2 years of therapy in both TN and TE patients. These differences were independent of changes in HIV-1 RNA and are evident with multiple different MVC-containing regimens.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.